Investigating how to improve immune therapy for pancreatic cancer by neutralizing tumor acidity
Imaging Acidosis and Immune Therapy in PDAC
This study is looking at how the acidity of pancreatic cancer tumors might make it harder for immune treatments to work, and it aims to see if a new therapy that reduces this acidity can help boost the effectiveness of these treatments for patients with this tough-to-treat cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project ID | NIH-10769757 on NIH RePORTER |
What this research studies
This research focuses on pancreatic ductal adenocarcinoma (PDAC), a highly lethal cancer that often resists treatments, including immune therapies. The study aims to explore the role of tumor acidity in inhibiting the effectiveness of immune cells, particularly T cells. By using a targeted therapy that neutralizes tumor acidity, the researchers hope to enhance the response to immune therapies in mouse models of PDAC. The ultimate goal is to find a viable treatment approach that can improve patient outcomes in this challenging cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma who are seeking new treatment options.
Not a fit: Patients with other types of cancer or those who do not have pancreatic ductal adenocarcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with pancreatic cancer by improving the efficacy of immune therapies.
How similar studies have performed: Previous studies have shown promise in using similar approaches to enhance immune therapy effectiveness, although this specific method is still being tested.
Where this research is happening
Tampa, United States
- H. Lee Moffitt Cancer Ctr & Res Inst — Tampa, United States (Active)
Researchers
- Principal investigator: Pilon-Thomas, Shari — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Pilon-Thomas, Shari
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.